Bazedoxifene is a medication used in the treatment and management of osteoporosis. First approved by the FDA in 2013 as a combination drug, this drug primarily targets postmenopausal women, the population most susceptible to bone loss defects. Bazedoxifene belongs to a family of drug compounds known as selective estrogen receptor modulators. This activity reviews the indications, mechanism of action, route of administration, adverse events, and other key elements (e.g., off-label uses, dosing, pharmacodynamics, pharmacokinetics, monitoring, and relevant interactions) pertinent to healthcare providers in the management of patients with osteoporosis and related menopausal symptoms.

**Objectives:**
- Highlight the indicated use for bazedoxifene.
- Describe the mechanism of action of bazedoxifene.
- Identify the potential adverse effects associated with bazedoxifene.
- Discuss the importance of interprofessional communication amongst healthcare team members and its relevance in enhancing patient outcomes following the administration of bazedoxifene for osteoporosis.